Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Onset of multiple sclerosis before adulthood leads to failure of age-expected brain growth.
Selective inhibition of the mitochondrial permeability transition pore protects against neuro-degeneration in experimental multiple sclerosis.
Fatal Acute Myeloid Leukemia With 11q23 MLL Gene Rearrangement Following Mitoxantrone Treatment in a Case of Childhood-onset Multiple Sclerosis.
Synthetic Biologics Reports Results of Independent Third Party Evaluations of Trimesta™ Data from Investigator-Sponsored Phase 2 Clinical Trial for Relapsing-Remitting Multiple Sclerosis
New multiple sclerosis phenotypic classification.
Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study.
Molecular mechanism underlying the impact of vitamin D on disease activity of MS.
Genzyme’s Lemtrada Approved by the FDA
Novel therapies for memory cells in autoimmune diseases.
Immune response during interferon beta-1b treatment in patients with multiple sclerosis who experienced relapses and those who were relapse-free in the START study.
Multiple sclerosis: risk factors, prodromes, and potential causal pathways.
[Results of a comparative clinical trial of the Russian Β - interferon-1b bioanalogue (infibeta)].
Natalizumab treatment during pregnancy - effects on the neonatal immune system.
IgE-Mediated Allergic Reactions after the First Administration of Glatiramer Acetate in Patients with Multiple Sclerosis.
Rituximab, an anti-CD20 monoclonal antibody: History & mechanism: Off label rituximab use in transplant patients
Pregnancy outcomes in patients exposed to interferon beta-1b.
Translating Fatigue to Human Performance.
Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome.
New approaches in the management of multiple sclerosis.
Multiple sclerosis in children: an update on clinical diagnosis, therapeutic strategies, and research.
US court permits generic version of Teva MS drug a year sooner
Fourth PML Case With Tecfidera in MS Calls for Vigilance
TGFβ Signaling Regulates the Timing of CNS Myelination by Modulating Oligodendrocyte Progenitor Cell Cycle Exit through SMAD3/4/FoxO1/Sp1.
Pharmacology and therapeutic potential of interferons.
First-in-class thyrotropin-releasing hormone (TRH)-based compound binds to a pharmacologically distinct TRH receptor subtype in human brain and is effective in neurodegenerative models.

Pages